HCPCS code Q5125: Releuko injection, per 1 mcg2026 Medicare rate & RVUs in Massachusetts
Reports filgrastim-ayow, a filgrastim biosimilar used to support neutrophil production, with each billing unit representing 1 microgram.
CMS doesn’t publish an office rate for Q5125 in Massachusetts.
Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.
Your location
On this page 9 sections
What Q5125 covers
Q5125 identifies filgrastim-ayow (Releuko), a biosimilar medicine that stimulates neutrophil production. It is used in oncology care to reduce neutropenia-related infection risk in patients receiving myelosuppressive cancer treatment. Clinicians administer filgrastim by subcutaneous injection or intravenous infusion; oncology and hematology practices, infusion centers, and hospitals may report the drug when furnished to a patient.
For Medicare, Q5125 has physician fee schedule status E and is excluded from that schedule. When covered, it is a Part B drug generally paid using CMS quarterly ASP drug pricing files. Coverage is left to the Medicare contractor’s judgment. Each unit represents 1 microgram of filgrastim-ayow, so the reported unit count corresponds to the administered dose in micrograms.
This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.
Where Q5125 pays more and less in Massachusetts
| Payment locality | Office | Facility |
|---|---|---|
| Metropolitan Boston, MA | Unavailable | Unavailable |
| Rest of Massachusetts | Unavailable | Unavailable |
How the Q5125 rate is calculated
Each of Q5125’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.
How the rate is built · Q5125
RVUs × geographic indexes × conversion factor
Work0.00
0.00 RVUs× 1.000 GPCI
Practice expense0.00
0.00 RVUs× 1.000 GPCI
Malpractice0.00
0.00 RVUs× 1.000 GPCI
Adjusted RVUs
0.0000
Conversion factor
$33.4009
Medicare rate
$0.00
Every GPCI starts at 1.000, the national rate. Enter a ZIP or drag a slider.
Payment rules and modifiers for Q5125
Q5125 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.
Place of service · Q5125
Which rate does Medicare pay?
The POS code on the claim line (CMS-1500 box 24B).
POS 11 · non-facility rate · national
—
Q5125 isn’t priced in this setting.
Q5125 compared with similar codes
Compare codes · National
4 codes, side by side
How to choose
- Q5101Zarxio injectionPer 1 mcg
- Use Q5101 for filgrastim-sndz; Q5125 identifies filgrastim-ayow. Both are filgrastim biosimilars and use a 1-microgram unit.
- Q5110NivestymPer 1 mcg
- Q5110 identifies filgrastim-aafi, while Q5125 identifies filgrastim-ayow. Select the code matching the product administered.
- Q5120Pegfilgrastim-bmezPer 0.5 mg
- Q5120 identifies pegfilgrastim-bmez, a longer-acting related medicine reported in 0.5-mg units. Q5125 identifies filgrastim-ayow in 1-microgram units.
Q5125 billing questions
What drug does Q5125 identify?
It identifies filgrastim-ayow, marketed as Releuko, a biosimilar to filgrastim. It is used to stimulate neutrophil production.
How many units should be reported?
Each unit represents 1 microgram. Calculate units from the administered dose in micrograms.
How does Q5125 differ from Q5101 or Q5110?
Those codes identify different filgrastim biosimilars: Q5101 is filgrastim-sndz, and Q5110 is filgrastim-aafi. Q5125 is specific to filgrastim-ayow.
Does Medicare pay Q5125 under the physician fee schedule?
No. CMS assigns status E, excluding the code from the physician fee schedule. When covered, it is a Part B drug generally paid using CMS quarterly ASP drug pricing files.
Does Medicare automatically cover the drug?
No. Coverage is left to the Medicare contractor’s judgment.
Where these rates come from
FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.
CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027
Fee sheets · Coming soon
Put Q5125 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist